AnGes, Inc. (TYO:4563)
Japan · Delayed Price · Currency is JPY 58.00
0.00 (0.00%)
At close: Mar 6, 2026
AnGes Revenue
In the year 2025, AnGes had annual revenue of 874.00M JPY with 35.93% growth. AnGes had revenue of 228.00M in the quarter ending December 31, 2025, with 32.56% growth.
Revenue
874.00M
Revenue Growth
+35.93%
P/S Ratio
26.25
Revenue / Employee
15.89M
Employees
55
Market Cap
22.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 874.00M | 231.00M | 35.93% |
| Dec 31, 2024 | 643.00M | 491.00M | 323.03% |
| Dec 31, 2023 | 152.00M | 85.00M | 126.87% |
| Dec 31, 2022 | 67.00M | 3.00M | 4.69% |
| Dec 31, 2021 | 64.00M | 25.00M | 64.10% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RaQualia Pharma | 3.98B |
| ReproCELL | 2.52B |
| Japan Tissue Engineering | 2.26B |
| Immuno-Biological Laboratories | 1.03B |
| Stella Pharma | 968.00M |
| CellSeed | 161.00M |
| Nano Holdings | 155.00M |
| Renascience | 107.00M |